April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart. The valve was designed for excellent hemodynamic performance (the optimization of blood flow through the valve) and long-term durability. To ensure the structural integrity of the valve, it is constructed using a polyester and tissue-covered titanium stent, or base. The valve features leaflets manufactured from pericardial tissue attached to the exterior of the valve stent. This design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve and limiting tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact. Also contributing to the valve’s durability, it offers the Linx AC Technology, an anticalcification treatment designed to reduce tissue mineralization (hardening), one of the primary causes of valve deterioration. It also offers several features that improve the ease of implantation, including the valve’s unique holder, designed to improve visibility and cuff access for suturing, and customized sizes. “Physicians around the world have already voiced tremendous excitement and satisfaction with the Trifecta valve,” said Frank J. Callaghan, president of the St. Jude Medical cardiovascular division. “Trifecta has demonstrated outstanding hemodynamic performance and has improved the lives of patients with aortic valve disease.” The valve was approved by regulatory authorities in Europe and Canada in 2010. For more information: www.sjm.com
Technology | April 22, 2011
FDA Clears Trifecta Stented Tissue Aortic Valve
News | Cardiovascular Surgery| August 25, 2016
August 25, 2016 — Simulation training fo
Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
Sponsored Content | Videos | Heart Valve Technology| August 15, 2016
The Edwards Lifesciences Intuity Elite surgical aortic valve uses a balloon expandable skirt technology taken from th
Technology | Heart Valve Technology| August 15, 2016
August 15, 2016 – Edwards Lifesciences announced the U.S.
News | Cardiovascular Surgery| August 08, 2016
ClearFlow Inc. announced in late July that its PleuraFlow Active Clearance Technology is now available for the...
News | Heart Valve Technology| August 05, 2016
August 5, 2016 — The Centers for Medicare and Medicaid Services (CMS) has reassigned MitraClip transcatheter mitral v
Feature | Heart Valve Technology| August 04, 2016
August 4, 2016 — Medtronic announced CE (Conformité Européenne) mark market clearnace for the self-expanding, recaptu
News | Heart Valve Technology| July 27, 2016
Edwards Lifesciences Corp. announced that Health Canada has approved the Edwards Sapien 3 transcatheter heart valve for...
News | Business| July 26, 2016
July 26, 2016 — The Centers for Medicare & Medicaid Services (CMS) has proposed the creation of new...
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...